United States Hereditary Angioedema Therapeutics Market Report and Forecast 2024-2032

According to the report, the United States hereditary angioedema therapeutics market is projected to grow at a CAGR of 8.20% between 2024 and 2032 reaching a value of around USD 1256.28 million by 2032. Aided by the heightened awareness about the rare genetic disorder, advancements in drug development, and the push for early diagnosis, the market is expected to grow significantly by 2032.

Hereditary Angioedema is a rare, genetic disorder characterised by recurrent episodes of severe swelling (angioedema) in the skin, intestines, and airways. The swift and unpredictable onset of symptoms can often be debilitating and, in some cases, life-threatening. In the United States, the focus on HAE therapeutics has intensified in recent years, with several FDA-approved treatments entering the market.

One of the primary drivers of the United States hereditary angioedema therapeutics market growth is the heightened advocacy and awareness campaigns by organisations, patient groups, and medical professionals. These initiatives have illuminated the significance of early diagnosis and timely treatment, thus accelerating the demand for therapeutic solutions.

Parallelly, the U.S. has been at the forefront of research and development in the realm of HAE therapeutics. Leading pharmaceutical companies, buoyed by grants and favourable regulations, have been channelling efforts into creating innovative drug solutions, both prophylactic and acute. The increasing number of drug approvals and the robust pipeline of drugs in clinical trials further pose a positive impact on the United States hereditary angioedema therapeutics market outlook.

Moreover, the market's expansion has been underpinned by the growing emphasis on personalised medicine. With HAE manifesting differently across patients, there is a rising demand for treatments tailored to individual patient profiles. Consequently, biopharmaceutical firms are investing in genomics and precision medicine to design drugs that cater to specific patient subsets.

Medical advancements, however, have not been the sole driver of the United States hereditary angioedema therapeutics market demand. Technology, especially digital health platforms, has played a pivotal role in the evolution of the HAE therapeutics market. Mobile applications and telehealth services are facilitating symptom tracking, ensuring medication adherence, and fostering better patient-doctor communication, thereby enhancing the overall management of the disorder.

The United States market for hereditary angioedema therapeutics is at a significant inflection point. With the synergistic combination of medical research, technological advancements, and heightened awareness, the market is poised for substantial growth in the coming years. As more is understood about the genetic underpinnings of HAE and as drug portfolios diversify, the future looks promising for patients and stakeholders alike in the realm of HAE therapeutics.

Market Segmentation

The market can be divided based on drug type and route of administration.

Market Breakup by Drug Type

• C1-Esterase Inhibitor
• Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others

Market Breakup by Route of Administration

• Intravenous
• Subcutaneous
• Oral

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the United States hereditary angioedema therapeutics market. Some of the major players explored in the report are as follows:

• Takeda Pharmaceutical Company Limited
• BioCryst Pharmaceuticals, Inc.
• Sanofi S.A.
• CSL Behring LLC.
• Pharming Group N.V.
• Cipla Inc.
• Ionis Pharmaceuticals Inc.
• Attune Pharmaceuticals, Inc.
• Adverum Biotechnologies, Inc
• Others